Hematology-Oncology Associates of the Quad-Cities, PC
Colorectal Cancer Trials
NSABP R-04: Treatment With 5fu continuous infusion, or 5FU infusion + xeloda, or xeloda alone, or XELOX Combined With Radiation Therapy For Patients With Rectal Cancer
E5202: A Randomized Phase III Study Comparing 5-FU, Leucovorin and Oxaliplatin versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers
CALGB 80502 A Phase II Trial of Irinotecan and AZD2171 (CALGB IND #101263)
in Patients with Metastatic Colorectal Cancer After Progression on FOLFOX Plus
Cetuximab or FOLFOX Plus Bevacizumab and Cetuximab
CALGB 80502: A Phase II Trial of Irinotecan and AZD2171
in Patients with Metastatic Colorectal Cancer After Progression on FOLFOX Plus Cetuximab or FOLFOX Plus Bevacizumab and Cetuximab (after progression on CALGB 80405)
E5202: A Randomized Phase III Study Comparing 5-FU, Leucovorin and Oxaliplatin versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers
CALGB 80502 A Phase II Trial of Irinotecan and AZD2171 (CALGB IND #101263)
in Patients with Metastatic Colorectal Cancer After Progression on FOLFOX Plus
Cetuximab or FOLFOX Plus Bevacizumab and Cetuximab
CALGB 80502: A Phase II Trial of Irinotecan and AZD2171
in Patients with Metastatic Colorectal Cancer After Progression on FOLFOX Plus Cetuximab or FOLFOX Plus Bevacizumab and Cetuximab (after progression on CALGB 80405)
